Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · IEX Real-Time Price · USD
0.835
-0.012 (-1.39%)
At close: Jul 19, 2024, 4:00 PM
0.848
+0.013 (1.53%)
Pre-market: Jul 22, 2024, 8:20 AM EDT
Achilles Therapeutics Employees
As of December 31, 2023, Achilles Therapeutics had 215 total employees, including 204 full-time and 11 part-time employees. The number of employees decreased by 27 or -11.16% compared to the previous year.
Employees
215
Change (1Y)
-27
Growth (1Y)
-11.16%
Revenue / Employee
n/a
Profits / Employee
-$299,688
Market Cap
34.32M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 215 | -27 | -11.16% |
Dec 31, 2022 | 242 | -10 | -3.97% |
Dec 31, 2021 | 252 | 93 | 58.49% |
Dec 31, 2020 | 159 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Nutex Health | 800 |
Exagen | 179 |
Retractable Technologies | 151 |
Aadi Bioscience | 89 |
IceCure Medical | 77 |
iCAD, Inc. | 69 |
IGC Pharma | 67 |
Unicycive Therapeutics | 14 |
ACHL News
- 2 months ago - Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines - GlobeNewsWire
- 2 months ago - Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning - GlobeNewsWire
- 6 months ago - Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference - GlobeNewsWire
- 7 months ago - Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction - GlobeNewsWire
- 8 months ago - Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewsWire